Notice of General Meeting

19 November 2019

NMC Health plc

(the "Company" or "NMC")

Proposed Share Buyback and Directors' Remuneration Policy - Notice of General Meeting

NMC Health plc ("NMC" or the "Company") announces that it will today be posting a circular to shareholders (the "Circular") convening a general meeting to consider:

·; a general authority to make market purchases of NMC shares in line with the Company's intention announced on 22 August 2019; and

·; a proposed directors' remuneration policy, which the Company is required to adopt in place of its existing policy, which was previously approved in December 2016.

Copies of the Circular, including the notice of general meeting to be held at 11.00am on 5 December 2019 at the offices of Allen & Overy LLP, One Bishops Square, London E1 6AD, United Kingdom, will be available on the Company's website (https://nmc.ae/investorrelations/shareholderinformation).

A letter from the Joint Chairmen of the Company, and from the Chairman of the Remuneration Committee, and the expected timetable of principal events are also contained in the Circular.

A copy of the Circular has been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm.

For further enquiries, please contact:

About NMC Health

NMC is the leading private healthcare operator in the GCC with an international network of healthcare facilities across 19 countries. NMC ranks as one of the top two in-vitro fertilisation ("IVF") operators globally. The Group is recognised as a leading provider of long-term medical care in the UAE through its subsidiary ProVita. Pursing a selective international expansion program since 2016, the company now has total capacity of 3,109 beds across its network with 48% of this capacity in the Kingdom of Saudi Arabia (KSA), where the company has introduced long-term and multi-specialty care services. Moreover, the recent formation of a joint venture with GOSI/Hassana Investment Company provides a solid platform for continued growth in the GCC region's largest healthcare market. NMC treated over 7.5m patients in 2018. The Group is also a leading UAE supplier of products and consumables across several key market segments, with the major contribution coming from healthcare related products. The Group reported revenues of US$2.1 billion for the year ended 31 December 2018.

In April 2012 NMC was listed on the Premium Segment of the London Stock Exchange. NMC is a constituent of the FTSE 100 Index.